GLP-1 Reduces Heavy Drinking in Clinical Trial
Weekly semaglutide with CBT significantly reduced heavy drinking in alcohol use disorder & obesity patients, per a clinical trial.
04 May 2026
Weekly semaglutide with CBT significantly reduced heavy drinking in alcohol use disorder & obesity patients, per a clinical trial.
GLP-1 meds cause significant fat loss with minimal muscle loss over 12 months, proving their weight management efficacy.
